GIP Agonists and Blockers in Obesity

A new paper on GIP receptor targeting in obesity is a structured narrative review. It reports no new clinical trial. The authors ask why drugs that activate the GIP receptor and drugs that block it can both support weight loss when paired with GLP-1 receptor activation. They conclude that the two routes probably work through different neural circuits, while stressing that the mechanisms remain incompletely validated in humans^[1].

The clinical examples are also different medicines, not opposite versions of one experiment. Tirzepatide activates both GIP and GLP-1 receptors. Maridebart cafraglutide, also called MariTide, combines GLP-1 receptor agonism with an antibody that blocks GIP receptors. Both have produced weight loss in randomized trials, but nobody has run a head-to-head trial that isolates which GIP strategy is better^[1].

What the review actually did

The authors searched PubMed/MEDLINE and ClinicalTrials.gov from database inception through 1 August 2026. They screened basic, translational and clinical evidence across selective GIP receptor modulation, combined GIP and GLP-1 receptor modulation, and use after metabolic or bariatric surgery^[1]. That makes this a synthesis of several evidence types. It does not report a newly randomized group, a fresh intervention or a new patient outcome.

A review can connect findings across studies, while each claimed mechanism still depends on the design and limits of the underlying experiment. Here, the neural-circuit evidence comes mainly from mice. The human evidence comes from multi-receptor medicines whose separate components cannot be cleanly credited for the full result.

Primary mouse studies split the pathways

A 2025 Nature Metabolism study tested GIP receptor agonists and antagonists in several genetically altered mouse lines. Activating GIP receptors lowered food intake and body weight without requiring GLP-1 receptor signalling. Blocking GIP receptors behaved differently: its effects disappeared in mice lacking GLP-1 receptors, and its brainstem gene-expression pattern resembled GLP-1 receptor activation rather than GIP receptor activation^[2].

The same paper found that the antagonist effect survived when GIP receptors were removed from GABAergic neurons, a class of inhibitory brain cells implicated in the agonist response. The authors therefore argued against the idea that prolonged stimulation simply desensitizes the receptor and turns an agonist into a functional blocker^[2]. The chronic drug experiments were limited to male mice with diet-induced obesity and glucose intolerance. That keeps the result mechanistic and preclinical, not proof of the same circuit in people.

A 2026 follow-up used region-specific receptor deletion. Removing GIP receptors from the area postrema, a brainstem region that senses circulating signals, reduced the appetite response to a long-acting GIP agonist. Removing them from the hypothalamus instead erased the extra weight-loss effect seen when a GIP antagonist was added to liraglutide, a GLP-1 receptor agonist^[3]. The study included male and female mice in some experiments, but its chronic high-fat-diet work used male mice because female mice gained less weight in that model.

Human trials support two drug designs

Human trials show that both design strategies can produce weight loss, though they do not prove that GIP activation and blockade are equally effective. In SURMOUNT-1, 2,539 adults with obesity or overweight and no diabetes were randomized to tirzepatide or placebo for 72 weeks. Mean weight change ranged from a 15.0% reduction with the 5 mg dose to 20.9% with 15 mg, compared with 3.1% on placebo^[5]. Tirzepatide is one molecule with activity at both receptors, so the trial cannot assign a separate share of the outcome to its GIP component.

The phase 2 maridebart cafraglutide trial randomized 592 participants across cohorts with and without type 2 diabetes. Among 465 participants without diabetes, mean weight change at week 52 ranged from a 12.3% to 16.2% reduction across active regimens, compared with 2.5% on placebo. Among 127 participants with diabetes, the active-regimen range was 8.4% to 12.3%, compared with 1.7% on placebo^[4]. Gastrointestinal adverse events were common, though less frequent with dose escalation and a lower starting dose.

These trials cannot be compared as if they were two arms of one study. They used different molecules, schedules, populations and protocols. Maridebart cafraglutide also carries its GLP-1 agonist peptides on an antibody scaffold, while tirzepatide is a dual-receptor peptide. Both designs have clinical evidence, but neither trial assigns its result to GIP receptor direction alone.

The current label covers agonism only

Current US labeling provides a separate regulatory answer. Zepbound contains tirzepatide, and its label identifies the medicine as a GIP and GLP-1 receptor agonist. The label covers chronic weight reduction in adults with obesity, or overweight plus at least one weight-related condition, and treatment of moderate to severe obstructive sleep apnea in adults with obesity^[6]. The tirzepatide regulation table tracks status across the jurisdictions we cover.

That label does not endorse GIP receptor antagonism, explain which receptor contributes how much to tirzepatide's effect or establish a general rule that either direction will work. Maridebart cafraglutide remains an investigational medicine. A promising phase 2 result is clinical evidence, but it is not a marketing authorization or a treatment recommendation.

What remains unsettled

The evidence has clear boundaries. In mice, GIP receptor activation and blockade reach weight regulation through separable brain pathways. In people, one approved co-agonist and one investigational agonist-antagonist conjugate have each produced weight loss. The bridge between those statements remains incomplete^[1].

A clean test would need selective agents, matched GLP-1 receptor activity and direct measures that can separate appetite, energy expenditure, fat mass, lean mass and tolerability. Post-bariatric populations need their own studies because surgery changes incretin physiology. Until then, receptor direction is a useful research question, not a shortcut for predicting which drug will work better for an individual.

This article is for educational and journalistic purposes only and does not constitute medical advice. Tirzepatide is a prescription medicine, and maridebart cafraglutide is investigational. Consult a qualified healthcare professional before making any treatment decision. PeptideMethods.com does not sell, distribute or facilitate the sale of any peptide product.